Trastuzumab has tumoricidal efficacy through both antibody-dependent cellular cytotoxicity (ADCC), as well as inhibition of tumor cells’ innate HER2-mediated signaling pathway, blocking downstream effects of cell proliferation and angiogenesis [24]. The gene discussed is ERBB2; the disease is neoplasm.